2026 Q2 - tulosraportti
53 päivää sitten
‧53 min
2,35 DKK/osake
Viimeisin osinko
1,52%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 875 | - | - | ||
| 971 | - | - | ||
| 33 | - | - | ||
| 21 | - | - | ||
| 86 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 5.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 6.11.2025 | ||
2025 Q2 - tulosraportti 21.8.2025 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·1.10. · MuokattuTaken from Euroinvestor today, 1.10.26: Shares in one of Denmark's largest C25 companies are receiving a string of buy recommendations. As many as 17 out of 19 analysts now have buy recommendations on the stock, while the remaining two have hold recommendations, according to data from Bloomberg on Thursday morning. Since the start of the year, the stock has risen by a total of a good 6 pct. and has fallen by a little over 7 pct. over the past month. Based on this, the price on Thursday morning, before trading begins, stands at 419.5 kr. Analysts believe this price will be beaten within the next 12 months. Looking at the analysts' average price target, i.e., the level they estimate on average that the stock will reach within the next 12 months, they expect the stock to reach 509.8 kr. from the current price of 419.5 kr. This corresponds to analysts overall seeing a price potential of 21 pct. in the stock. This concerns the stock in Novonesis, which among other things develops and produces enzymes and microorganisms. Taking a closer look at the list of buy recommendations, one finds SEB Bank, which has a price target of 560 kr. According to the bank's assessment, the stock holds a price potential of 33 pct. within the next 12 months. This is followed by Jefferies, JP Morgan, and Nordea Bank, all with buy recommendations and the same price target of 540 kr.- ·29.9. · MuokattuNovonesis is scaling up the production facility. It is a super good sign that the business is doing well and we can probably expect a higher share price, even though it has dropped a bit lately. I am leaning back and enjoying the ride :) Some have probably become impatient and thought we are at the peak - I certainly do not think we are...... Novonesis is carrying out a major expansion in Wisconsin Close yesterday at 15:58 ∙ MarketWire Novonesis has completed a major expansion of the production facility in West Allis, Wisconsin. Novonesis writes this in an announcement on Monday afternoon. The investment increases the company's production capacity in North America for dairy cultures and raises fermentation capacity by approximately 66 pct. and packaging capacity by 17 pct. At the same time, West Allis will become one of the world's largest production plants for lactobacillus. .\˙ MarketWire
28.9.Why does this keep falling?
Because the company's name has something to do with Novo.... Investors don't like that.
·25.9.Funny how this stock is so affected by the status of the Strait of Hormuz (energy prices and fertilizer). The whole philosophy of creating a sustainable company that creates more output with less input goes down the drain as long as oil is cheap enough :D
·25.9.Novonesis gets its price target raised by a little over 20 pct. by the American major bank Citi, which now expects to see Novonesis trade at a price of 530 kr. within the coming 12 months. Thus, Citi expects a price potential of 19,7% According to Marketwire, Citi calls the Danish ingredient manufacturer a "structural growth machine" which is "supported by high returns, leading organic growth and substantial reinvestments".
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 276 417 | 276 417 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 276 417 | 276 417 | 0 | 0 |
2026 Q2 - tulosraportti
53 päivää sitten
‧53 min
2,35 DKK/osake
Viimeisin osinko
1,52%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1.10. · MuokattuTaken from Euroinvestor today, 1.10.26: Shares in one of Denmark's largest C25 companies are receiving a string of buy recommendations. As many as 17 out of 19 analysts now have buy recommendations on the stock, while the remaining two have hold recommendations, according to data from Bloomberg on Thursday morning. Since the start of the year, the stock has risen by a total of a good 6 pct. and has fallen by a little over 7 pct. over the past month. Based on this, the price on Thursday morning, before trading begins, stands at 419.5 kr. Analysts believe this price will be beaten within the next 12 months. Looking at the analysts' average price target, i.e., the level they estimate on average that the stock will reach within the next 12 months, they expect the stock to reach 509.8 kr. from the current price of 419.5 kr. This corresponds to analysts overall seeing a price potential of 21 pct. in the stock. This concerns the stock in Novonesis, which among other things develops and produces enzymes and microorganisms. Taking a closer look at the list of buy recommendations, one finds SEB Bank, which has a price target of 560 kr. According to the bank's assessment, the stock holds a price potential of 33 pct. within the next 12 months. This is followed by Jefferies, JP Morgan, and Nordea Bank, all with buy recommendations and the same price target of 540 kr.
- ·29.9. · MuokattuNovonesis is scaling up the production facility. It is a super good sign that the business is doing well and we can probably expect a higher share price, even though it has dropped a bit lately. I am leaning back and enjoying the ride :) Some have probably become impatient and thought we are at the peak - I certainly do not think we are...... Novonesis is carrying out a major expansion in Wisconsin Close yesterday at 15:58 ∙ MarketWire Novonesis has completed a major expansion of the production facility in West Allis, Wisconsin. Novonesis writes this in an announcement on Monday afternoon. The investment increases the company's production capacity in North America for dairy cultures and raises fermentation capacity by approximately 66 pct. and packaging capacity by 17 pct. At the same time, West Allis will become one of the world's largest production plants for lactobacillus. .\˙ MarketWire
- 28.9.Why does this keep falling?Because the company's name has something to do with Novo.... Investors don't like that.
- ·25.9.Funny how this stock is so affected by the status of the Strait of Hormuz (energy prices and fertilizer). The whole philosophy of creating a sustainable company that creates more output with less input goes down the drain as long as oil is cheap enough :D
- ·25.9.Novonesis gets its price target raised by a little over 20 pct. by the American major bank Citi, which now expects to see Novonesis trade at a price of 530 kr. within the coming 12 months. Thus, Citi expects a price potential of 19,7% According to Marketwire, Citi calls the Danish ingredient manufacturer a "structural growth machine" which is "supported by high returns, leading organic growth and substantial reinvestments".
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 875 | - | - | ||
| 971 | - | - | ||
| 33 | - | - | ||
| 21 | - | - | ||
| 86 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 5.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 6.11.2025 | ||
2025 Q2 - tulosraportti 21.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 276 417 | 276 417 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 276 417 | 276 417 | 0 | 0 |
2026 Q2 - tulosraportti
53 päivää sitten
‧53 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 5.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 6.11.2025 | ||
2025 Q2 - tulosraportti 21.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
2,35 DKK/osake
Viimeisin osinko
1,52%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1.10. · MuokattuTaken from Euroinvestor today, 1.10.26: Shares in one of Denmark's largest C25 companies are receiving a string of buy recommendations. As many as 17 out of 19 analysts now have buy recommendations on the stock, while the remaining two have hold recommendations, according to data from Bloomberg on Thursday morning. Since the start of the year, the stock has risen by a total of a good 6 pct. and has fallen by a little over 7 pct. over the past month. Based on this, the price on Thursday morning, before trading begins, stands at 419.5 kr. Analysts believe this price will be beaten within the next 12 months. Looking at the analysts' average price target, i.e., the level they estimate on average that the stock will reach within the next 12 months, they expect the stock to reach 509.8 kr. from the current price of 419.5 kr. This corresponds to analysts overall seeing a price potential of 21 pct. in the stock. This concerns the stock in Novonesis, which among other things develops and produces enzymes and microorganisms. Taking a closer look at the list of buy recommendations, one finds SEB Bank, which has a price target of 560 kr. According to the bank's assessment, the stock holds a price potential of 33 pct. within the next 12 months. This is followed by Jefferies, JP Morgan, and Nordea Bank, all with buy recommendations and the same price target of 540 kr.
- ·29.9. · MuokattuNovonesis is scaling up the production facility. It is a super good sign that the business is doing well and we can probably expect a higher share price, even though it has dropped a bit lately. I am leaning back and enjoying the ride :) Some have probably become impatient and thought we are at the peak - I certainly do not think we are...... Novonesis is carrying out a major expansion in Wisconsin Close yesterday at 15:58 ∙ MarketWire Novonesis has completed a major expansion of the production facility in West Allis, Wisconsin. Novonesis writes this in an announcement on Monday afternoon. The investment increases the company's production capacity in North America for dairy cultures and raises fermentation capacity by approximately 66 pct. and packaging capacity by 17 pct. At the same time, West Allis will become one of the world's largest production plants for lactobacillus. .\˙ MarketWire
- 28.9.Why does this keep falling?Because the company's name has something to do with Novo.... Investors don't like that.
- ·25.9.Funny how this stock is so affected by the status of the Strait of Hormuz (energy prices and fertilizer). The whole philosophy of creating a sustainable company that creates more output with less input goes down the drain as long as oil is cheap enough :D
- ·25.9.Novonesis gets its price target raised by a little over 20 pct. by the American major bank Citi, which now expects to see Novonesis trade at a price of 530 kr. within the coming 12 months. Thus, Citi expects a price potential of 19,7% According to Marketwire, Citi calls the Danish ingredient manufacturer a "structural growth machine" which is "supported by high returns, leading organic growth and substantial reinvestments".
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 875 | - | - | ||
| 971 | - | - | ||
| 33 | - | - | ||
| 21 | - | - | ||
| 86 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 276 417 | 276 417 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 276 417 | 276 417 | 0 | 0 |